“FH is much more common than we once thought...” -- Dr. Josh Knowles Familial hypercholesteremia (FH) affects 1 in every 220 people across all ages and ethnic backgrounds. As you’ll hear in this American Heart Association podcast, that’s at least 1.3 million Americans and as few as 10%

In a survey of nearly 1,200 patients presented at #ACC24, oral lipid-lowering therapies were “significantly more preferred to all injectable regimens.” We continue to advance our pipeline of investigational oral options for lowering LDL-C. bit.ly/3YkENFN

Statins alone aren’t enough to get many people to their LDL-C goals. As Steve Nicholls notes, we need additional lipid-lowering therapy options to help reduce the global burden of cardiovascular disease.

Terry Simpson John Kastelein AD is a crystallopathy - cholesterol crystals are toxic to all cells including the brain -

Thank you to the hundreds of patients and investigators across ten countries who participated in our Phase 3 BROOKLYN trial. Your support moves us closer to our goal of helping people at risk for cardiovascular disease. bit.ly/4fk9iSn

🚀 Exciting news from NewAmsterdam Pharma Corporation! Their Phase 3 BROOKLYN trial for Obicetrapib in HeFH patients showed remarkable results: LDL-C reduced by 36.3% at 84 days and 41.5% at 365 days! This is a significant milestone in treating HeFH! ir.newamsterdampharma.com/news-releases/…

Patients with HeFH are often diagnosed in adulthood, after decades of living with elevated LDL-C. Getting them to their LDL-C goals is critical, and currently available therapies aren’t always enough.

Heterozygous familial hypercholesterolemia (HeFH) is a common genetic condition characterized by very high LDL-C levels. Our Phase 3 BROOKLYN study reported positive results this week on LDL-C reduction in HeFH.

Before and after xanthoma regression in a patient with the Lebanese FH mutation. Interventional lipidology works much better than plastic surgery.

Thomas Dayspring I’m honestly just wondering if this calculation is reasonable and if the numbers pass the smell test. I can’t do this math. The computer did it. Dr Alo, DO, FACC Sek Kathiresan MD William Cromwell, MD Dr. James Underberg Michael Davidson MD Simon Hill MSc, BSc (Hons) John Kastelein

A new Nature Reviews Cardiology publication reinforces the growing consensus that with LDL-C, “lower is better, and earlier is better,” suggesting that cumulative exposure to LDL can be used as a biomarker to estimate cardiovascular risk. Explore the evidence and practical applications:

Can someone tell Rogan that the brain synthesizes all of its cholesterol and gets zero from the gut or from circulating in plasma lipoproteins. CLUELESS

Tom Stiles Dr. Ford Brewer Dr Brad Stanfield I'll rephrase - no clinician who knows what they are doing uses the large doses of niacin which have been proven to be totally ineffective in reducing Major Adverse Cardiovascular Events and which also have multiple clinical adversities

Developing more options for our lipid-lowering toolbox is important for patients and providers alike. We need to do everything in our power to help more people reach and maintain their LDL-C goals.

Austin Dudzinski, PharmD, BCACP John Kastelein Terry Simpson Simon Hill MSc, BSc (Hons) Sure. No biomarker predicts risk 100%/guarantees dz or not. But no other risk factor, in absence of all others can cause atherosclerosis all by itself, except ApoB containing lipoproteins. That’s why it reigns supreme. Not treating extremely high levels of ApoB bc CAC=0: bad med

Jake R. Austin Dudzinski, PharmD, BCACP John Kastelein Terry Simpson Simon Hill MSc, BSc (Hons) Talk to John Kastelein about his experience in the Netherlands with children with FH. Not a damn thing wrong with those kids with the exception that they lack the ability to clear LDL particles. Exposure to atherogenic lipoproteins was all that was required to wreak havoc

George Takei All the wonderful things he does for humanity and because you disagree with his politics you hate him. Have a good look in the mirror.

This week, we’re hosting two CME-accredited symposia at #ESCCongress2024 covering CETP as a therapeutic target in the clinical management of LDL-C and the use of novel therapies in LDL-C lowering. bit.ly/4dzvZRf

The non-HDL-C (which comes free) here is 94, so you already knew discordance was present (vs LDL-C 67) before you checked apoB. So, the pt must have high Lp(a), which likely should have been checked before apoB. So it's an incomplete case and does not make the point an apoB was